The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.
Schwarz
Kathleen B
KB
Department of Pediatrics, Division of Gastroenterology and Nutrition, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. kschwarz@jhmi.edu
Gonzalez-Peralta
Regino P
RP
Murray
Karen F
KF
Molleston
Jean P
JP
Haber
Barbara A
BA
Jonas
Maureen M
MM
Rosenthal
Philip
P
Mohan
Parvathi
P
Balistreri
William F
WF
Narkewicz
Michael R
MR
Smith
Lesley
L
Lobritto
Steven J
SJ
Rossi
Stephen
S
Valsamakis
Alexandra
A
Goodman
Zachary
Z
Robuck
Patricia R
PR
Barton
Bruce A
BA
D000293:Adolescent; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005260:Female; D016174:Hepacivirus / Q000187:drug effects; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009503:Neutropenia / Q000139:chemically induced; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D012367:RNA, Viral / Q000032:analysis / Q000187:drug effects; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a